Concord, the agentic media buying platform, announced a $3 million seed funding round on June 23, 2026, backed by A16Z Scout, Drysdale, Motier Ventures, Better Angle, and industry angels. The capital injection aims to accelerate the development of Concord Agent, a product designed to automate the last manual processes in media buying by turning briefs into live campaigns and managing pacing and optimization across major platforms simultaneously. This funding positions the company to become the execution infrastructure for major media budgets, enabling media buyers to focus on strategy rather than manual operations.

The platform integrates natively with DV360, Meta, YouTube, Amazon DSP, The Trade Desk, TikTok, and Google Ads. It currently serves advertisers within the WPP and Havas agency footprints globally. Early adopters of the technology have reported saving up to 70% of the time previously required for the manual buying loop involving execution, optimization, and reporting.

Investor Validation and Strategic Vision

The round drew validation from prominent figures in the adtech sector, including Rémi Lemonnier, co-founder of Scibids AI, which was acquired by DoubleVerify. Lemonnier described Concord as the missing execution layer of the industry, noting that while the decisioning layer has been built, the execution infrastructure required for the next era of media buying has been absent until now.

Mathias Adam at A16Z Scout characterized Concord's buying agents as the "killer app" for programmatic marketing. He emphasized that the platform automates complex tasks across every major platform simultaneously, representing a foundational shift rather than an incremental fix to the existing programmatic stack.

Leadership and Future Plans

Concord was co-founded by Nathan Venezia, CEO, who previously founded and sold Manadge to iHeartMedia. The leadership team includes Nicolas Cosson as CTO and Antoine Chwalek as Head of Engineering, both of whom previously built the adtech platform at Adot. Venezia stated that the company is building the necessary infrastructure to replace the manual work currently spread across disconnected platforms.

The new funding will be utilized to accelerate product development, expand platform coverage, and grow the team. Concord intends to scale its presence across the US and EMEA regions as it deploys its execution architecture for the intelligence era of media buying.

Concord Drugs Limited reported a consolidated net profit of ₹105.50 lakh for the financial year ended March 31, 2026, marking a substantial increase from ₹33.62 lakh in the previous year. Revenue from operations surged to ₹7,877.13 lakh, compared to ₹4,525.91 lakh in FY25, primarily driven by higher net sales. The company’s Board of Directors approved the standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held on May 27, 2026.

Financial Performance

For the quarter ended March 31, 2026, the company reported a consolidated net profit of ₹52.80 lakh, up from ₹3.90 lakh in the corresponding period of the previous year. Net sales from operations for the quarter stood at ₹3,788.80 lakh, a significant rise from ₹1,039.17 lakh in Q4FY25. Total expenses for the year increased to ₹7,729.81 lakh from ₹4,456.77 lakh in the prior year, attributed to higher costs of material consumed and employee benefit expenses.

Capital Structure and Equity

During the quarter ended December 31, 2025, the company issued 31,75,000 equity shares at a price of ₹36.30 per share on a preferential basis. Additionally, 20,25,000 warrants were allotted at ₹36.30 per warrant, with 25% of the upfront amounting to ₹1,83,76,875 received during the period. Consequently, the paid-up equity share capital increased to ₹1,317.50 lakh as of March 31, 2026, from ₹1,000.00 lakh in the previous year.

Auditor’s Observations

Pundarikashyam and Associates, the statutory auditors, highlighted an emphasis of matter regarding long outstanding trade receivables of ₹4.14 crore in the books of accounts for more than two years, for which no provision for bad or doubtful debts has been made. The auditors also noted that balances of trade receivables, deposits, loans, advances, and trade payables are subject to confirmation from respective parties and consequential reconciliation or adjustment. Closing stocks are considered in the books based on management representation and are subject to verification.

Consolidated Financial Results

The following table summarizes the key financial metrics for the consolidated results for the year ended March 31, 2026:

The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013. The auditors confirmed that the results give a true and fair view of the company's financial performance.